CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022
- Revenue from primary healthcare business remained resilient with a drop of 7.3% despite massive lock-downs in China in 2022- Excluding non-cash impairment loss on investment in associate, loss after tax remained largely unchanged at RMB7.3 million from a year ago- Cash position strengthened by 62% to RMB39.4 million, while cash flow from operating activities was strong at a positive RMB16.0 million vs RMB1.1 million a year ago- Business climate in 2023/24 expected to improve significantly as China abandons zero-Covid policy with all hospitals and polyclinics fully operational SINGAPORE, Mar ...